Small Pharma Inc.: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom. | Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom. | ||
__INDEX__ | |||
Latest revision as of 17:57, 20 August 2022
Summary edit edit source
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom.